Detection of metallo β-lactamase production and antibiotic resistance with E-test method in pseudomonas, acinetobacter and klebsiella strains, in Turkey

Journal of Infection and Chemotherapy

Volumn 10, Issue 5, 2004, Pages 257-261

  Toraman, Zulal Asci ^a   Yakupogullari, Yusuf ^a   Kizirgil, Ahmet ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Acinetobacter s.p.; Antimicrobial susceptibility; Carbapenems; Klebsiella s.p.; Metallo lactamases; Pseudomonas s.p.

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CIPROFLOXACIN; ISEPAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; TIMENTIN; TOBRAMYCIN;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; ENZYME SYNTHESIS; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; IN VITRO STUDY; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; TURKEY (REPUBLIC);

EID: 11244260787     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-004-0333-3     Document Type: Article

References (26)

1. Livermore DM. Detection of beta-lactamase mediated resistance. J Antimicrob Chemother 2001;48(Suppl 1):59-66.
2. Poirel L, Nordman P. Acquired carbapenem-hydrolysing beta-lactamases and their genetic support. Curr Pharm Biotechnol 2002;3:117-27.
3. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs 2002;3:218-24.
4. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000;3:489-95.
5. Watanabe M, Iyobe S, Inoeu M, Mitsuashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991;35:147-51.
6. Ricco ML, Francescini N, Boschi L, Caravelli B, Cornaglia G, Fontana R, et al. Characterization of the MBL determinant of Acinetobacter baumanii AC-54/97 reveals the existence of bla-IMP allelic variants carried by gene cassettes of different phylogeny. Antimicrob Agents Chemother 2000;44:1229-35.
7. Chu YW, Afzal-Shah M, Hovang ETS, Palepou MFI, Lyon DJ, Woodford N, et al. IMP-4, a novel MBL from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998. Antimicrob Agents Chemother 2001;45:710-4.
8. Lauretti L, Ricco ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, et al. Cloning and characterization of bla-VIM, a new integron-borne MBL gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 1999;43:1584-90.
9. Cornoglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable MBL. Clin Infect Dis 2000;31:1119-25.
10. Livermore DM. Acquired carbapenemases. J Antimicrob Chemother 1997;39:673-6.
11. National Committee for Clinical Laboratory Standards (NCCLS), Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7. Philadelphia: NCCLS; 2001.
12. Pfaller MA, Jones RN, Biedenbach DJ. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn Microbiol Infect Dis 2001;41:177-82.
13. Walsh TR, Blomstrom A, Qwarnstrom A, Gales A. Evaluation of a new Etest for detecting MBLs in routine clinical testing. J Clin Microbiol 2002;40:2755-9.
14. Kahan F, Kropp MH, Sundelof JG, Birnboum J. Thienamycin: development of imipenem-cilastatin. Antimicrob Agents Chemother 1983;12(Suppl D):1-35.
15. Bradley J, Garana SJ, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999;11:93-100.
16. Livermore DM. Of pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001;47:247-50.
17. Kurokawa H, Yagi T, Shibata N, Shibayama K, Arakawa Y. Worldwide proliferation of carbapenem-resistant Gram-negative bacteria. Lancet 1999;354:955.
18. Yan JJ, Ko WC, Tsai SH, Wu HM, Wu JJ. Outbreak of infection with multidrug resistant Klebsiella pneumoniae carrying bla-IMP-8 in a university medical center in Taiwan. J Clin Microbiol 2001; 39:4433-9.
19. Nordman P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002;8:321-31.
20. Payne DJ, Rodriguez JAH, Boyd H, Concha NO, Janson CA, Gilpin M. et al. Identification of a series of tricyclic natural products as potent broad spectrum inhibitors of MBLs. Antimicrob Agents Chemother 2002;46:1880-6.
21. Lee K, Lim JB, Yum JH, Yong D, Chong Y, Kim JM, et al. Blavim-2 cassette-containing novel integrons in MBL producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother 2002;46:1053-8.
22. Lee K, Lee HS, Kang HS, Jang SJ, Park AJ, Song WK, et al. Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and Gram-negative bacilli to third generation cephalosporin. imipenem and fluoroquinolone. J Korean Med Sci 2001;16:262-70.
23. Bellais S, Mimoz O, Leotard S, Jacolot A, Petitjean O, Nordman P. Efficacy of beta-lactams for treating experimentally induced pneumonia due to carbapenem hydrolysing MBL-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46:2032-4.
24. Toraman ZA, Yakupogullari Y. Carbapenemase producing Pseudomonas aeruginosa and ciprofloxacin use in neonatal intensive care unit. J Hosp Infect 2003;54:164-5.
25. Oh EJ, Lee S, Park YJ, Park JJ, Park K, Kim SI, et al. Prevalence of metallo beta-lactamase among Pseudomonas aeruginosa and Acinetobacter baumanii in a Korean university hospital and comparison of screening methods for detecting metallo beta-lactamase. J Microbiol Methods 2003;54:411-8.
26. Sasaki M, Hiyama E, Takesue M, Kodaira M, Sueda T, Yokoyama T. Clinic surveillance of surgical imipenem resistant Pseudomonas aeruginosa infection in a Japanese hospital. J Hosp Infect 2004; 56:111-8.